234 related articles for article (PubMed ID: 17659863)
1. An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Segatore B; Perilli M; Larosa M; Setacci D; Celenza G; Amicosante G
Int J Antimicrob Agents; 2007 Oct; 30(4):374-6. PubMed ID: 17659863
[No Abstract] [Full Text] [Related]
2. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
Prasad SV; Ballal M; Shivananda PG
Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
[TBL] [Abstract][Full Text] [Related]
3. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
Lister PD; Wolter DJ
Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
[TBL] [Abstract][Full Text] [Related]
5. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Burgess DS; Hall RG
Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide.
Sonnet P; Izard D; Mullié C
Int J Antimicrob Agents; 2012 Jan; 39(1):77-80. PubMed ID: 21974858
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Solak S; Willke A; Ergönül O; Tekeli E
Int J Antimicrob Agents; 2005 Feb; 25(2):181-2. PubMed ID: 15664492
[No Abstract] [Full Text] [Related]
8. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
Hansen GT; Zhao X; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
[TBL] [Abstract][Full Text] [Related]
9. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
[TBL] [Abstract][Full Text] [Related]
10. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Tennenberg AM; Davis NB; Wu SC; Kahn J
Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
[TBL] [Abstract][Full Text] [Related]
11. [The in vitro activity of ciprofloxacin against clinically-isolated strains of Pseudomonas aeruginosa and comparison with some other antibiotics].
Sener B; Hayran M; Kocagöz T; Ustaçelebi S
Mikrobiyol Bul; 1990 Apr; 24(2):120-5. PubMed ID: 2128529
[TBL] [Abstract][Full Text] [Related]
12. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
Parte AC; Smith JT
Microbios; 1994; 80(322):31-9. PubMed ID: 7854197
[TBL] [Abstract][Full Text] [Related]
13. [Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002].
De Vecchi E; Drago L; Nicola L; Colombo A; Guerra A; Tocalli L; Medaglia M; Gismondo MR
Infez Med; 2003 Dec; 11(4):196-200. PubMed ID: 14988667
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Schito AM; Schito GC
J Chemother; 2004 Apr; 16 Suppl 2():3-7. PubMed ID: 15255554
[No Abstract] [Full Text] [Related]
15. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Kanellakopoulou K; Sarafis P; Galani I; Giamarellou H; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2008 Jul; 32(1):33-9. PubMed ID: 18538547
[TBL] [Abstract][Full Text] [Related]
16. Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Prabhu RM; Elliott MA; Patel R
Clin Infect Dis; 2004 Apr; 38(7):1043-5. PubMed ID: 15034845
[No Abstract] [Full Text] [Related]
17. Enhanced bacterial uptake and bactericidal properties of ofloxacin loaded on bioadhesive hydrogels against Pseudomonas aeruginosa.
Romero VL; Manzo RH; Alovero FL
J Chemother; 2010 Oct; 22(5):328-34. PubMed ID: 21123156
[TBL] [Abstract][Full Text] [Related]
18. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin in vitro activity alone and in combination against clinical isolates of glucose nonfermenting bacteria.
Marklein G; Lotze G; Ungerechts J
J Chemother; 1989 Jul; 1(4 Suppl):156-9. PubMed ID: 16312350
[No Abstract] [Full Text] [Related]
20. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Jones RN; Beach ML; Pfaller MA
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):161-3. PubMed ID: 11750171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]